Medicare AdvantagePrior AuthLow impact
Fruzaqla (fruquintinib) (Revised)
Humana·Oncology, Gastroenterology·Medicare Advantage
Effective date
Jan 24, 2024
We identified it
Jun 24, 2026
Summary
New prior authorization policy for Fruzaqla (fruquintinib) capsules for Medicare Advantage members with metastatic colorectal cancer, requiring specific prior chemotherapy treatments and anti-VEGF/anti-EGFR therapies before approval. Policy excludes members who have already had disease progression on Fruzaqla.
Action Required
Immediately: Update prior authorization protocols for Fruzaqla (fruquintinib) capsules for Medicare Advantage members. Verify patients have metastatic colorectal cancer diagnosis and confirm prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, anti-VEGF therapy, and anti-EGFR therapy (if KRAS/NRAS wild-type). Submit prior authorization requests through Humana's system before prescribing. Claims will be denied without proper prior authorization.